214 related articles for article (PubMed ID: 17690854)
1. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
Capobianco M; Malucchi S; di Sapio A; Gilli F; Sala A; Bottero R; Marnetto F; Doriguzzi Bozzo C; Bertolotto A
Neurol Sci; 2007 Aug; 28(4):209-11. PubMed ID: 17690854
[TBL] [Abstract][Full Text] [Related]
2. [Failure of rituximab in relapsing neuromyelitis optica: case report with two-year prospective follow-up].
Cassinotto C; Joux J; Chausson N; Smadja D; Cabre P
Rev Neurol (Paris); 2008 Apr; 164(4):394-7. PubMed ID: 18439934
[TBL] [Abstract][Full Text] [Related]
3. Devic's neuromyelitis optica: clinical and imaging findings.
Vandevyver V; Lemmerling M; De Potter R; Verstraete K
JBR-BTR; 2007; 90(4):284-7. PubMed ID: 17966247
[TBL] [Abstract][Full Text] [Related]
4. Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica.
Sánchez-Carteyron A; Alarcia R; Ara JR; Martín J
Neurology; 2010 May; 74(18):1471-3. PubMed ID: 20439850
[No Abstract] [Full Text] [Related]
5. Devic's neuromyelitis optica: a clinicopathological study of 8 patients.
Mandler RN; Davis LE; Jeffery DR; Kornfeld M
Ann Neurol; 1993 Aug; 34(2):162-8. PubMed ID: 8338340
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab, Neuromyelitis Optica, and Tuberculosis: We Live An Era of Challenging Combinations.
Goncalves MV; Melo LH; Benedet CM; Ribas FD; Cabral NL; Fragoso YD
CNS Neurosci Ther; 2015 Nov; 21(11):914-5. PubMed ID: 26404521
[No Abstract] [Full Text] [Related]
7. A patient with a benign course of neuromyelitis optica (Devic's syndrome) over 12 years: MRI follow up and histological findings.
Köller H; Neuen-Jacob E; Saleh A; Kieseier BC; Jander S; Hartung HP
J Neurol; 2006 Jun; 253(6):819-20. PubMed ID: 16511648
[No Abstract] [Full Text] [Related]
8. MR imaging of Devic's neuromyelitis optica.
Filippi M; Rocca MA
Neurol Sci; 2004 Nov; 25 Suppl 4():S371-3. PubMed ID: 15727237
[TBL] [Abstract][Full Text] [Related]
9. Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Berger JR; Neltner J; Smith C; Cambi F
Mult Scler Relat Disord; 2014 Nov; 3(6):728-31. PubMed ID: 25891552
[TBL] [Abstract][Full Text] [Related]
10. Devic's neuromyelitis optica in an infant case.
Yuksel D; Senbil N; Yilmaz D; Yavuz Gurer YK
J Child Neurol; 2007 Sep; 22(9):1143-6. PubMed ID: 17890418
[TBL] [Abstract][Full Text] [Related]
11. Importance of cerebrospinal fluid examination in differential diagnosis of Devic's neuromyelitis optica by multiple sclerosis.
Bergamaschi R
Neurol Sci; 2003 Oct; 24(3):95-6. PubMed ID: 14600818
[No Abstract] [Full Text] [Related]
12. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population.
Furukawa Y; Yoshikawa H; Yachie A; Yamada M
Eur J Neurol; 2006 Jun; 13(6):655-8. PubMed ID: 16796591
[TBL] [Abstract][Full Text] [Related]
14. [Devic's neuromyelitis optica. Presentation of 2 new cases and review of the bibliography].
Carod Artal FJ; Brenner C; Melo M; del Negro MC; Pereira R
Neurologia; 2000; 15(7):307-12. PubMed ID: 11075580
[TBL] [Abstract][Full Text] [Related]
15. Devic's syndrome and primary APS: a new immunological overlap.
Squatrito D; Colagrande S; Emmi L
Lupus; 2010 Oct; 19(11):1337-9. PubMed ID: 20504834
[TBL] [Abstract][Full Text] [Related]
16. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
17. Images in neuroscience. Devic's disease.
Petty S; Mitchell P
J Clin Neurosci; 2004 Jan; 11(1):59-60. PubMed ID: 14642368
[No Abstract] [Full Text] [Related]
18. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
[TBL] [Abstract][Full Text] [Related]
19. Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report.
Ghezzi A; Baldini S; Zaffaroni M; Leoni G; Koudriavtseva T; Casini AR; Zeviani M
Neurol Sci; 2004 Nov; 25 Suppl 4():S380-2. PubMed ID: 15727239
[TBL] [Abstract][Full Text] [Related]
20. [Devic's neuromyelitis optica: an evolving concept].
de Seze J
Rev Neurol (Paris); 2006 May; 162(5):565-6. PubMed ID: 16710122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
